Diagnosis and treatment of polycystic ovary syndrome

Disorders of the menstrual cycle are common during the reproductive years. Variations in cycle length, flow, and frequency may be physiologic or reflect underlying pathology. When menstrual irregularities are persistent, progressive, or associated with other signs and symptoms (for example, acne, excess hair growth, weight gain, or infertility), evaluation by a clinician is warranted. One of the most common endocrine disorders in reproductive‑age persons with ovaries is polycystic ovary syndrome (PCOS), which affects an estimated 6–12% of women of reproductive age depending on diagnostic criteria used. PCOS is a leading cause of ovulatory dysfunction, menstrual irregularity, and infertility, and is associated with long‑term metabolic and cardiovascular risk (ACOG; NIH; Mayo Clinic; Cleveland Clinic).

This article reviews the epidemiology and pathophysiology of PCOS, clinical presentation, diagnostic evaluation (including differential diagnoses), and evidence‑based therapeutic options for reproductive, dermatologic, metabolic, and long‑term health management.

Epidemiology and clinical significance

PCOS is among the most common endocrine disorders in women of reproductive age. Prevalence estimates vary with the diagnostic criteria applied; population‑based studies using Rotterdam criteria typically report prevalence between 6% and 12%. PCOS is associated with:

Menstrual irregularity or oligomenorrhea/amenorrhea
Anovulatory infertility
Clinical or biochemical hyperandrogenism (acne, hirsutism, elevated androgens)
Metabolic abnormalities including insulin resistance, impaired glucose tolerance, type 2 diabetes, dyslipidemia, and obesity
Increased risk of nonalcoholic fatty liver disease and obstructive sleep apnea
Elevated lifetime risk for endometrial hyperplasia and, in some populations, endometrial carcinoma due to prolonged unopposed estrogen exposure from chronic anovulation

Early recognition and multidisciplinary management can reduce short‑term symptoms and minimize long‑term cardiometabolic and reproductive sequelae (ACOG; NIH; Mayo Clinic; Cleveland Clinic).

Pathophysiology

PCOS is a heterogeneous syndrome rather than a single disease. The exact etiologic mechanisms are incompletely understood, but current models emphasize the interaction of genetic predisposition with environmental and metabolic factors. Key pathophysiologic features include:

Ovarian hyperandrogenism: The ovaries often produce an excess of androgens (testosterone and androstenedione), driven by dysregulated luteinizing hormone (LH) secretion and intrinsic ovarian theca cell hyperactivity.
Insulin resistance and hyperinsulinemia: Many persons with PCOS have insulin resistance independent of body mass index (BMI). Hyperinsulinemia augments ovarian androgen production and reduces hepatic sex hormone‑binding globulin (SHBG), increasing circulating free androgens.
Anovulation: Abnormal follicular development and disrupted gonadotropin dynamics lead to chronic anovulation; multiple small antral follicles may be present on ultrasound.
Adipose tissue dysfunction and low‑grade inflammation: Excess adiposity, particularly visceral fat, contributes to metabolic disturbance and inflammation, exacerbating PCOS features.

Because PCOS represents a spectrum, not every patient has all hallmarks; some patients have predominant metabolic features, others primarily dermatologic or reproductive manifestations (NIH; ACOG; Mayo Clinic).

Clinical presentation and symptoms

PCOS may present at various points across the reproductive lifespan. Common presentations include:

Menstrual irregularity: Oligomenorrhea (infrequent cycles), amenorrhea (absence of menses), or irregular bleeding due to chronic anovulation.
Hyperandrogenic signs: Hirsutism (excess terminal hair in a male pattern distribution), acne, and less commonly male‑pattern hair thinning. Biochemical hyperandrogenism may be present even without marked clinical features.
Polycystic ovarian morphology (PCOM) on pelvic ultrasound: Increased antral follicle count or ovarian volume; note that ultrasound findings alone are not diagnostic of PCOS in the absence of other criteria.
Infertility associated with anovulation.
Metabolic features: Weight gain or difficulty losing weight; features of insulin resistance such as acanthosis nigricans (velvety hyperpigmented plaques, commonly on the neck or axillae); dyslipidemia; glucose intolerance.
Psychosocial issues: Increased prevalence of depression, anxiety, and diminished quality of life.

Symptoms typically emerge during adolescence or early reproductive years, often becoming more apparent when menstrual cycles do not normalize after menarche, or when fertility is sought (ACOG; Mayo Clinic; Cleveland Clinic).

Diagnostic criteria

There are three dominant diagnostic frameworks used in clinical practice; the Rotterdam criteria are most commonly applied in general gynecology and research settings.

Rotterdam criteria (2003): Diagnosis requires two of three features after exclusion of other disorders:

Oligo‑ and/or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovarian morphology on ultrasound

NIH 1990 criteria: Requires both clinical/biochemical hyperandrogenism and oligo/anovulation; ultrasound is not required.

Androgen Excess and PCOS Society (AE-PCOS) criteria: Requires hyperandrogenism (clinical or biochemical) plus ovarian dysfunction (oligo/anovulation and/or polycystic ovaries).

Selection of criteria can affect prevalence estimates and management decisions. Importantly, in adolescents, diagnostic criteria require caution because physiologic anovulation and multifollicular ovaries are common in the early post‑menarcheal years; many experts recommend requiring both persistent hyperandrogenism and persistent anovulation (beyond 2–3 years post‑menarche) before labeling PCOS (ACOG; NIH; Cleveland Clinic).

Diagnostic evaluation: history, examination, and investigations

A structured evaluation confirms the diagnosis, excludes other causes of hyperandrogenism or ovulatory dysfunction, and assesses metabolic and reproductive risks.

Medical history

Obtain a comprehensive history including:

Menstrual history (age at menarche, cycle length, frequency, and characteristics)
Reproductive history and fertility goals
Symptoms of hyperandrogenism (onset and progression of acne, hair growth, alopecia)
Weight history, dietary patterns, exercise, and sleep
Medications (including hormonal contraception, antipsychotics, steroids, insulin sensitizers) and herbal supplements
Family history of PCOS, diabetes, early coronary artery disease, or infertility
Symptoms suggestive of other endocrine disorders (e.g., Cushing syndrome, thyroid disease)

Physical examination

Vital signs including blood pressure
Anthropometrics: height, weight, BMI, waist circumference
Skin: acne, acanthosis nigricans, androgenic alopecia
Hair growth: assess hirsutism using a standardized scale (e.g., modified Ferriman‑Gallwey score) where appropriate
Pelvic examination when indicated

Laboratory testing

The following baseline tests are typically recommended when PCOS is suspected:

Pregnancy test (urine or serum beta‑hCG) to exclude pregnancy as cause of amenorrhea
Serum total testosterone and/or free androgen index to document biochemical hyperandrogenism; timing in the early follicular phase is preferred when feasible
Serum dehydroepiandrosterone sulfate (DHEA‑S) if rapid virilization or very high androgen levels suggest adrenal source
Thyroid‑stimulating hormone (TSH) to exclude thyroid dysfunction
Prolactin to exclude hyperprolactinemia
17‑hydroxyprogesterone (17‑OH progesterone) in selected cases to screen for nonclassical congenital adrenal hyperplasia (particularly with elevated androgens)
Fasting glucose and fasting insulin (or HbA1c) to assess baseline glycemic status; consider a 2‑hour oral glucose tolerance test (OGTT) for persons with BMI ≥25 kg/m², family history of type 2 diabetes, or other risk factors (NIH; ACOG)
Lipid profile to assess cardiovascular risk
Liver enzymes if concerns for nonalcoholic fatty liver disease (NAFLD)
Consider sleep assessment for symptoms of sleep apnea

Interpretation of androgen assays depends on the laboratory’s reference ranges. Mild biochemical hyperandrogenism is common and may be functionally significant even when within upper limits of normal.

Pelvic ultrasound

Transvaginal pelvic ultrasound can identify polycystic ovarian morphology (increased antral follicle count [≥20 follicles per ovary by current high‑resolution ultrasound standards] or ovarian volume >10 cm³). Use of ultrasound should be individualized:

Ultrasound is useful to document ovarian morphology but is not required to establish the diagnosis when clinical and laboratory criteria are sufficient.
Ultrasound criteria are not reliable in adolescents and may overdiagnose PCOS.
Polycystic ovarian morphology may be present in asymptomatic persons and does not by itself establish PCOS.

Excluding other causes (differential diagnosis)

Consider alternative or concomitant diagnoses that can mimic PCOS:

Thyroid dysfunction (hypothyroidism or hyperthyroidism)
Hyperprolactinemia
Nonclassical congenital adrenal hyperplasia (21‑hydroxylase deficiency)
Cushing syndrome
Androgen‑secreting neoplasms (ovarian or adrenal) — suspect with rapid onset or severe virilization and markedly elevated androgens
Medications that cause hyperandrogenism or menstrual irregularity (e.g., isotretinoin, danazol, antipsychotics)
Pregnancy

A targeted workup based on clinical features will usually exclude these conditions (ACOG; NIH; Mayo Clinic).

Management principles

Management of PCOS is individualized around the patient's presenting concerns and long‑term risks. Key objectives include:

Regulating menstrual cycles and protecting the endometrium to reduce the risk of hyperplasia
Treating hyperandrogenic symptoms (hirsutism, acne)
Managing metabolic risk (obesity, insulin resistance, dyslipidemia)
Addressing fertility desires when present
Supporting psychosocial health

Lifestyle interventions are foundational for all patients, with pharmacologic and procedural options layered according to symptom severity and goals.

Lifestyle modification

Lifestyle interventions are first‑line therapy for patients with overweight or obesity and contribute to improved menstrual regularity, ovulatory function, androgen levels, and metabolic profiles.

Weight loss: Even modest weight loss of 5–10% of body weight can restore ovulatory cycles and improve insulin sensitivity and hyperandrogenic symptoms.
Diet: Calorie‑restricted diets tailored to patient preferences; both low‑glycemic‑index and low‑fat approaches can be effective when sustained.
Exercise: Regular aerobic and resistance exercise improves insulin sensitivity independent of weight loss.
Behavioral strategies: Structured programs and support for sustained lifestyle change.

Lifestyle interventions should be integrated with behavioral counseling and referral to dietitians, exercise physiologists, or structured weight‑loss programs as needed (NIH; Mayo Clinic; Cleveland Clinic).

Pharmacologic management

Pharmacologic therapy is chosen to address menstrual irregularity, hyperandrogenism, metabolic abnormalities, or fertility desires.

Hormonal contraceptives (combined oral contraceptives or progestin‑only options)

Combined oral contraceptives (COCs) are first‑line therapy to regulate menstrual cycles and provide endometrial protection in patients who do not desire pregnancy. COCs also reduce androgenic symptoms by suppressing ovarian androgen production and increasing SHBG, thereby lowering free testosterone.
Progestin therapy (cyclic or continuous) can be used to induce withdrawal bleeding and protect the endometrium in those who cannot or do not wish to use estrogen‑containing contraception (for example, if there are contraindications to estrogen).
Choice of contraceptive should account for cardiovascular risk factors, smoking, age, and patient preference (ACOG; Mayo Clinic).

Insulin sensitizers — Metformin

Metformin improves insulin sensitivity and can reduce insulin levels and androgen concentrations. It has modest benefits on menstrual regularity and promotes weight and metabolic improvements.
Metformin may be particularly useful in patients with glucose intolerance or type 2 diabetes, and in those who do not tolerate or cannot use hormonal contraceptives.
While metformin can aid in the restoration of ovulation, it is not as effective as selective ovulation induction agents (see below) for fertility treatment (NIH; ACOG; Mayo Clinic).

Anti‑androgens

Spironolactone: A potassium‑sparing diuretic with anti‑androgenic effects; effective for hirsutism and acne when combined with contraception due to teratogenic risk (potential feminization of a male fetus) and contraceptives may be required.
Finasteride: A 5‑alpha reductase inhibitor used off‑label for hirsutism; also teratogenic and requires reliable contraception.
Oral anti‑androgens are used as adjuncts for persistent moderate to severe hirsutism or acne after at least 6 months of adequate hormonal therapy.
Topical therapies and cosmetic procedures (laser hair removal, electrolysis) may be used in combination with medical therapy for hair removal (Mayo Clinic; Cleveland Clinic).

Acne treatment

Topical retinoids, benzoyl peroxide, topical or systemic antibiotics, or systemic agents are used according to acne severity. Oral isotretinoin is effective for severe nodulocystic acne, but teratogenicity requires strict pregnancy prevention strategies.

Weight‑loss pharmacotherapy and bariatric surgery

For patients with severe obesity and comorbidities, weight‑loss pharmacotherapy (GLP‑1 receptor agonists, etc.) or bariatric surgery may be appropriate and can lead to significant improvements in menstrual regularity, fertility, and metabolic parameters.
Referral to multidisciplinary teams is recommended for evaluation (Cleveland Clinic; Mayo Clinic).

Fertility management

Fertility treatment is individualized based on patient age, duration of infertility, ovarian reserve, and patient preferences.

First-line ovulation induction

Letrozole (an aromatase inhibitor) is now widely recommended as first‑line pharmacologic ovulation induction for anovulatory infertility in PCOS, associated with higher live birth rates compared with clomiphene citrate (ACOG; ASRM guidance; NIH summaries).
Clomiphene citrate (a selective estrogen receptor modulator) has been used historically and remains an option when letrozole is unavailable or contraindicated.
Low‑dose gonadotropin therapy is reserved for clomiphene‑ or letrozole‑resistant cases but requires close monitoring for ovarian hyperstimulation and multiple gestation risk.

Adjunctive strategies

Metformin may be combined with ovulation induction in certain cases, particularly in patients with glucose intolerance or prior failure of clomiphene, though the benefits for live birth rates are modest.
Weight loss in overweight patients often improves ovulatory frequency and may restore spontaneous fertility.

Advanced reproductive technologies

Intrauterine insemination (IUI) combined with controlled ovarian stimulation may be considered in selected cases.
In vitro fertilization (IVF) is indicated for patients with failed medical management, concomitant tubal or male factor infertility, or other indications. IVF protocols may be adjusted in PCOS to minimize the risk of ovarian hyperstimulation syndrome (OHSS) (NIH; ACOG; Mayo Clinic).

Monitoring and long‑term health surveillance

PCOS is associated with lifelong health implications; ongoing monitoring is essential.

Metabolic screening

Screen for glucose intolerance at diagnosis: fasting glucose or 2‑hour OGTT is recommended in many guidelines, particularly for patients with BMI ≥25 kg/m² or additional diabetes risk factors. Repeat screening every 1–3 years depending on risk profile.
Annual or periodic screening for dyslipidemia and blood pressure measurement; counsel on cardiovascular risk reduction.
Assess for nonalcoholic fatty liver disease in patients with metabolic risk factors.

Endometrial health

Patients with oligo/amenorrhea are at increased risk for endometrial hyperplasia due to unopposed estrogen exposure. Endometrial protection with cyclic progestin or continuous combined hormonal contraception is advised.
Evaluate abnormal uterine bleeding with appropriate imaging and endometrial sampling when indicated (persistent bleeding, postmenopausal bleeding, or failed medical therapy).

Mental health

Screen for mood disorders: depression and anxiety are more prevalent in this population. Provide or arrange psychological support and treatment as indicated.

Reproductive planning and pregnancy

Preconception counseling: optimize weight, glycemic control, and manage comorbidities prior to conception. Women with PCOS have an increased risk of gestational diabetes, hypertensive disorders of pregnancy, and cesarean delivery; risk mitigation starts preconception.
Discontinue teratogenic anti‑androgens and ensure effective contraception prior to initiating such therapies.

Special considerations

Adolescents

Diagnosis in adolescents requires caution because normal pubertal development includes irregular cycles and polymorphic ovarian morphology. Most guidelines recommend delaying formal diagnosis until at least 2 years post‑menarche and require persistent hyperandrogenism and sustained oligo/amenorrhea. Management focuses on symptom control and counseling (ACOG; NIH).

Menopause

PCOS may persist beyond reproductive years with residual metabolic risk. Postmenopausal management centers on cardiovascular risk reduction and metabolic surveillance.

Potential complications and prognosis

PCOS is associated with a range of short‑ and long‑term complications:

Infertility due to chronic anovulation
Increased risk of type 2 diabetes and impaired glucose tolerance
Dyslipidemia and increased cardiovascular risk markers
Nonalcoholic fatty liver disease
Obstructive sleep apnea in patients with obesity
Endometrial hyperplasia and, less commonly, endometrial carcinoma
Psychological effects, including lowered quality of life and higher rates of depression and anxiety

With appropriate lifestyle interventions and targeted medical therapy, many patients experience meaningful improvement in symptoms, restoration of regular menses and ovulation, improved fertility outcomes, and reduced metabolic risk. Lifelong monitoring and collaborative care between primary care, endocrinology, gynecology, dermatology, and mental health professionals are often necessary (ACOG; NIH; Mayo Clinic; Cleveland Clinic).

Practical approach to a patient with suspected PCOS (summary)

Obtain a detailed history and perform focused physical examination.
Exclude pregnancy and other causes of menstrual irregularity and hyperandrogenism with appropriate laboratory testing.
Apply diagnostic criteria (e.g., Rotterdam) while taking age‑specific considerations into account.
Perform baseline metabolic screening (OGTT as indicated, fasting lipids) and assess cardiovascular risk.
Develop an individualized management plan that prioritizes lifestyle modification and addresses menstrual regulation, hyperandrogenic symptoms, metabolic risk, and fertility desires.
Provide education on long‑term health implications, contraception options, and when to seek further evaluation (e.g., rapid virilization, failure of therapy, or pregnancy planning).
Arrange regular follow‑up for symptom monitoring and metabolic surveillance.

Patient education and counseling

Effective management of PCOS requires shared decision‑making and clear patient education:

Explain the multifactorial nature of PCOS and that it is a chronic condition requiring ongoing management.
Emphasize the central role of lifestyle modification and realistic expectations around weight loss and symptom improvement.
Discuss medication options, expected benefits, side effects, and potential teratogenic risks (necessity for contraception when on anti‑androgens).
Provide resources for support, including nutrition counseling, behavioral therapy, and support groups as needed.
Encourage screening for mood disorders and provide referral to mental health services when appropriate.

References and resources

American College of Obstetricians and Gynecologists (ACOG) — practice resources on evaluation and management of PCOS.
National Institutes of Health (NIH) / National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — patient and clinician information on PCOS, metabolic risk, and fertility.
Mayo Clinic — clinical overview of PCOS diagnosis and treatment options.
Cleveland Clinic — patient guides on PCOS symptoms, testing, and management.

(For specific guideline documents and evidence summaries consult the ACOG practice bulletins, NIH/NIDDK publications, and reviews from major academic medical centers such as Mayo Clinic and Cleveland Clinic.)

This educational overview is intended to summarize current clinical approaches to diagnosis and management of PCOS. Individual patient care should be guided by detailed clinical assessment and discussion with relevant specialists.